Search clinical trials for: atezolizumab plus bevacizumab

Total 7713 results

Asan Medical Center
Seoul National University Hospital; Hanyang University; Soon Chun Hyang University

Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion (ALERT-HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IV

Korea, Republic of
CHA University

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy (HCC)

Hepatocellular Carcinoma

Korea, Republic of
CHA University
Hoffmann-La Roche

Completed

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Advanced Hepatocellular Carcinoma

Korea, Republic of
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
Tae Won Kim

Recruiting

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab (DYNAMIC)

Hepatocellular Carcinoma

Korea, Republic of
CHA University
Boryung Pharmaceutical Co., Ltd

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab (HCC)

Advanced Hepatocellular Carcinoma

Korea, Republic of
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Medical University of Vienna

Recruiting

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Hepatocellular Carcinoma

Austria
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Second... and other collaborators

Not yet recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Tumor Thrombus
Hospices Civils de Lyon

Recruiting

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST)

Gastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic Adenocarcinoma

France
Northwestern University
National Cancer Institute (NCI)

Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Hepatocellular Carcinoma

United States
Samsung Medical Center

Recruiting

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Hepatocellular Carcinoma | Portal Vein Thrombosis

Korea, Republic of
University Hospital, Essen

Recruiting

Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer (COMBATBIL)

Biliary Tract Cancer

Spain, Germany
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Genentech, Inc.

Completed

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Melanoma

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hoffmann-La Roche

Recruiting

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS)

Squamous Cell Carcinoma of the Anal Canal

Spain
Replimune Inc.
Roche Pharma AG

Active, not recruiting

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

MSS | pMMR | Refractory Metastatic Colorectal Cancer

United States
Azienda Ospedaliero, Universitaria Pisana

Completed

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (TRUST)

Rectal Cancer

Italy
Abramson Cancer Center at Penn Medicine

Recruiting

SBRT With Atezo/Bev for HCC

Hepatocellular Carcinoma

United States
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
National Taiwan University Hospital

Active, not recruiting

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

NSCLC Stage IIIB~IV

Taiwan
University of Rochester

Withdrawn

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Cancer of Liver

United States
Fundación GECP

Active, not recruiting

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA)

Non Small Cell Lung Cancer

Spain
Ludwig-Maximilians - University of Munich

Recruiting

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND)

Hepatocellular Carcinoma Non-resectable

Germany
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
Sun Yat-sen University

Completed

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
National Cancer Centre, Singapore
Hoffmann-La Roche; Sirtex Medical; Singapore Clinical Research Institute

Recruiting

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients (STRATUM)

Locally Advanced Hepatocellular Carcinoma

Korea, Republic of, Singapore
Japanese Foundation for Cancer Research
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION)

Breast Cancer

Japan
University of Texas Southwestern Medical Center
Genentech, Inc.

Recruiting

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST-B)

Hepatocellular Carcinoma

United States
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Shuhong Yi

Recruiting

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Recurrent Liver Cancer After Liver Transplantation

China
Fudan University
Roche Pharma AG

Recruiting

Efficacy and Safety of T+A+RAD in HCC

Hepatocellular Carcinoma

China
University Hospital, Montpellier

Recruiting

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02)

Hepatocellular Carcinoma

France
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Zhongda Hospital

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
Michael Dill
University of Cologne; German Cancer Research Center; Heidelberg University; Universitätsmedizin... and other collaborators

Not yet recruiting

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA)

Immunotherapy

Germany
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Astrocytoma of Brain

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer (CIRCUS)

Metastatic Colorectal Cancer

Italy
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa)

Metastatic Colorectal Cancer

Italy
Second Affiliated Hospital, School of Medicine,...

Recruiting

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colorectal Cancer

China
Fudan University

Recruiting

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Colorectal Cancer

China
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Recruiting

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)

Breast Cancer

France
Azienda Ospedaliero, Universitaria Pisana

Completed

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
Liaoning Tumor Hospital & Institute

Unknown

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Colorectal Cancer | Liver Metastases

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Rectal Cancer | Colon Cancer | Hepatic Metastases

United States

3

Subscribe